Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Data Collection and Analysis
2.3. Statistical Analysis
3. Results
3.1. Characteristics of the Survey Respondents
3.2. Tolerability of the First Dose of the BNT162b2 mRNA COVID-19 Vaccine in the COVID-19-Free Group
3.3. Tolerability of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in the COVID-19-Free Group
3.4. Tolerability of the First Dose of the BNT162b2 mRNA COVID-19 Vaccine in the COVID-19-Exposed Group
3.5. Tolerability of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in the COVID-19-Exposed Group
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wang, C.L.; Liu, Y.Y.; Wu, C.H.; Wang, C.Y.; Wang, C.H.; Long, C.Y. Impact of COVID-19 on Pregnancy. Int. J. Med. Sci. 2021, 18, 763–767. [Google Scholar] [CrossRef] [PubMed]
- Salem, D.; Katranji, F.; Bakdash, T. COVID-19 infection in pregnant women: Review of maternal and fetal outcomes. Int. J. Gynaecol. Obstet. 2021, 152, 291–298. [Google Scholar] [CrossRef] [PubMed]
- Jafari, M.; Pormohammad, A.; Sheikh Neshin, S.A.; Ghorbani, S.; Bose, D.; Alimohammadi, S.; Basirjafari, S.; Mohammadi, M.; Rasmussen-Ivey, C.; Razizadeh, M.H.; et al. Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: A systematic review and meta-analysis. Rev. Med. Virol. 2021, 31, 1–16. [Google Scholar] [CrossRef] [PubMed]
- De Oliveira, K.F.; de Oliveira, J.F.; Wernet, M.; Carvalho Paschoini, M.; Ruiz, M.T. COVID-19 and pregnancy: A scoping review on pregnancy characteristics and outcomes. Int. J. Nurs. Pract. 2021, 27, e12956. [Google Scholar] [CrossRef]
- Wei, S.Q.; Bilodeau-Bertrand, M.; Liu, S.; Auger, N. The impact of COVID-19 on pregnancy outcomes: A systematic review and meta-analysis. CMAJ 2021, 193, E540–E548. [Google Scholar] [CrossRef] [PubMed]
- Kotlyar, A.M.; Grechukhina, O.; Chen, A.; Popkhadze, S.; Grimshaw, A.; Tal, O.; Taylor, H.S.; Tal, R. Vertical transmission of coronavirus disease 2019: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2021, 224, 35–53.e3. [Google Scholar] [CrossRef] [PubMed]
- Donders, G.G.G.; Grinceviciene, S.; Haldre, K.; Lonnee-Hoffmann, R.; Donders, F.; Tsiakalos, A.; Adriaanse, A.; Martinez de Oliveira, J.; Ault, K.; Mendling, W. On The behalf of the Covid-Isidog Guideline Group. ISIDOG Consensus Guidelines on COVID-19 vaccination for women before, during and after Pregnancy. J. Clin. Med. 2021, 10, 2902. [Google Scholar] [CrossRef]
- Shook, L.L.; Fallah, P.N.; Silberman, J.N.; Edlow, A.G. COVID-19 Vaccination in Pregnancy and Lactation: Current research and gaps in understanding. Front. Cell Infect. Microbiol. 2021, 11, 735394. [Google Scholar] [CrossRef]
- Luxi, N.; Giovanazzi, A.; Capuano, A.; Crisafulli, S.; Cutroneo, P.M.; Fantini, M.P.; Ferrajolo, C.; Moretti, U.; Poluzzi, E.; Raschi, E.; et al. Ilmiovaccino COVID19 collaborating group. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf. 2021, 44, 1247–1269. [Google Scholar] [CrossRef]
- ACOG Vaccinating Pregnant and Lactating Patients against COVID-19. 2021. Available online: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19 (accessed on 3 December 2020).
- COVID-19 (Coronavirus Disease): People with Certain Medical Conditions. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed on 6 April 2021).
- COVID-19 (Coronavirus Disease): Information about COVID-19 Vaccines for People Who Are Pregnant or Breastfeeding. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html (accessed on 6 April 2021).
- Royal College of Obstetricians and Gynaecologists. Updated Advice on COVID-19 Vaccination in Pregnancy and Women Who Are Breastfeeding. Available online: https://www.rcog.org.uk/en/news/updated-advice-on-covid-19-vaccination-in-pregnancy-and-women-who-are-breastfeeding/ (accessed on 6 April 2021).
- PTGiP Position Statement on Vaccination of Pregnant Women against COVID19. Available online: https://www.ptgin.pl/sites/scm/files/2021-09/04.2021%20Stanowisko%20PTGiP%20dotyczące%20szczepień%20kobiet%20ciężarnych%20przeciwko%20COVID19.pdf (accessed on 24 April 2021).
- Damasceno, D.H.P.; Amaral, A.A.; Silva, C.A.; Simões, E.; Silva, A.C. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. Available online: https://pubmed.ncbi.nlm.nih.gov/34473613/ (accessed on 16 June 2021).
- Wainstock, T.; Yoles, I.; Sergienko, R.; Sheiner, E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine 2021, 39, 6037–6040. [Google Scholar] [CrossRef]
- Burd, I.; Kino, T.; Segars, J. The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: Considering maternal and neonatal benefits. J. Clin. Investig. 2021, 131, e150790. [Google Scholar] [CrossRef] [PubMed]
- Morales-Núñez, J.J.; Muñoz-Valle, J.F.; Meza-López, C.; Wang, L.F.; Machado Sulbarán, A.C.; Torres-Hernández, P.C.; Bedolla-Barajas, M.; De la O-Gómez, B.; Balcázar-Félix, P.; Hernández-Bello, J. Neutralizing antibodies titers and side effects in response to BNT162b2 vaccine in healthcare workers with and without prior SARS-CoV-2 infection. Vaccines 2021, 9, 742. [Google Scholar] [CrossRef] [PubMed]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- Vogel, W.H. Infusion reactions: Diagnosis, assessment, and management. Clin. J. Oncol. Nurs. 2010, 14, E10–E21. [Google Scholar] [CrossRef] [PubMed]
- Theiler, R.N.; Wick, M.; Mehta, R.; Weaver, A.L.; Virk, A.; Swift, M. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am. J. Obstet. Gynecol. MFM 2021, 3, 100467. [Google Scholar] [CrossRef] [PubMed]
- Raw, R.K.; Rees, J.; Kelly, C.A.; Wroe, C.; Chadwick, D.R. Prior COVID-19 infection is associated with increased adverse events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine. Vaccine 2021, 40, 418–423. [Google Scholar] [CrossRef] [PubMed]
- Baldolli, A.; Michon, J.; Appia, F.; Galimard, C.; Verdon, R.; Parienti, J.J. Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study. Vaccine 2021, 39, 4410–4413. [Google Scholar] [CrossRef]
- Orefice, R. Immunology and the immunological response in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2021, 76, 3–12. [Google Scholar] [CrossRef]
- Cornish, E.F.; Filipovic, I.; Åsenius, F.; Williams, D.J.; McDonnell, T. Innate immune responses to acute viral infection during pregnancy. Front. Immunol. 2020, 11, 572567. [Google Scholar] [CrossRef]
- Zdanowska, N.; Owczarczyk-Saczonek, A.B.; Zdanowski, W.; Placek, W.J. Interleukin 35: An overview. Pol. Ann. Med. 2020, 27, 225–229. [Google Scholar] [CrossRef]
- Krammer, F.; Srivastava, K.; Alshammary, H.; Amoako, A.A.; Awawda, M.H.; Beach, K.F.; Bermúdez-González, M.C.; Bielak, D.A.; Carreño, J.M.; Chernet, R.L.; et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. 2021, 384, 1372–1374. [Google Scholar] [CrossRef] [PubMed]
- Andrzejczak-Grządko, S.; Czudy, Z.; Donderska, M. Side effects after COVID-19 vaccinations among residents of Poland. Eur. Rev. Med. Pharmacol. Sci 2021, 25, 4418–4421. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.W.; Lim, S.Y.; Lee, J.H.; Lim, J.S.; Kim, M.; Kwon, S.; Joo, J.; Kwak, S.H.; Kim, E.O.; Kwon, H.S.; et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J. Korean Med. Sci. 2021, 36, e153. [Google Scholar] [CrossRef]
- Kim, L.; Whitaker, M.; O’Halloran, A.; Kambhampati, A.; Chai, S.J.; Reingold, A.; Armistead, I.; Kawasaki, B.; Meek, J.; Yousey-Hindes, K.; et al. Hospitalization rates and characteristics of children aged <18 Years hospitalized with laboratory-confirmed COVID-19 COVID-NET, 14 States, March 1–July 25, 2020. Morb Mortal Wkly Rep. 2020, 69, 1081–1088. [Google Scholar] [CrossRef]
- Beharier, O.; Mayo, R.P.; Raz, T.; Sacks, K.N.; Schreiber, L.; Suissa-Cohen, Y.; Chen, R.; Gomez-Tolub, R.; Hadar, E.; Gabbay-Benziv, R.; et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J. Clin. Investig. 2021, 131, e154834. [Google Scholar] [CrossRef]
- Zdanowski, W.; Waśniewski, T. Evaluation of SARS-CoV-2 spike protein antibody titers in cord blood after COVID-19 vaccination during pregnancy in Polish healthcare workers: Preliminary results. Vaccines 2021, 9, 675. [Google Scholar] [CrossRef]
Pregnant Women COVID-19 − | Non-Pregnant Women COVID-19 − | p | Total COVID-19 − | |
---|---|---|---|---|
Age, mean (SD) | 31.4 (+/−2.6) y | 33.1 (+/−3.6) y | 0.242 # | N/A |
BMI, mean (SD) | 22.75 (+/−3.59) kg/m2 | 21.7 (+/−3.38) kg/m2 | 0.098 # | N/A |
One dose of the vaccine administered, n (%) | 145 (100%) | 19 (100%) | N/A | 164 (100%) |
Two doses of the vaccine administered, n (%) | 105 (72.4%) | 18 (94.7%) | N/A | 123 (75%) |
Side effects after first dose | ||||
Vaccination site pain total, n (%) | 138 (94.5%) | 19 (100%) | 0.271 ^ | 157 (95.7%) |
Cutaneous reaction total, n (%) | 14 (9.7%) | 1 (4.8%) | 0.464 ^ | 15 (9.1%) |
Headache total, n (%) | 16 (11.0%) | 3 (14.3%) | 0.608 ^ | 19 (11.6%) |
On the first day, n (%) | 13 (9.0%) | 3 (14.3%) | 16 (9.8%) | |
Between the second and seventh days, n (%) | 3 (2.1%) | None | 3 (1.8%) | |
Fever | 0.234 ^ | |||
On the first day, n (%) | 2 (1.4%) | 1 (5.3%) | 3 (1.8%) | |
Between the second and seventh days, n (%) | None | None | None | |
Myalgia | 0.420 ^ | |||
On the first day, n (%) | 2 (1.4%) | 1 (4.8%) | 3 (1.8%) | |
Between the second and seventh days, n (%) | 3 (2.1%) | 1 (4.8%) | 4 (2.4%) | |
Fatigue up to the seventh day, n (%) | 51 (35.2%) | 6 (31.5%) | 0.701 ^ | 57 (34.7%) |
Gastrointestinal symptoms up to the seventh day | 0.061 ^ | |||
Total, n (%) | 3 (2.1%) | 2 (9.5%) | 5 (3.0%) | |
Nausea, n (%) | 3 (2.1%) | 2 (9.5%) | 5 (3.0%) | |
Vomiting, n (%) | None | None | None | |
Diarrhoea, n (%) | None | None | None | |
Side effects after second dose | ||||
Vaccination site pain total, n (%) | 93 (87.7%) | 18 (100) | 0.106 ^ | 21 (89.4%) |
Cutaneous reaction total, n (%) | 7 (6.7%) | 1 (5.3%) | 0.729 ^ | 8 (6.5%) |
Headache total, n (%) | 42 (31.4%) | 8 (47.4%) | 0.630 ^ | 50 (40.6%) |
On the first day, n (%) | 33 (31.4%) | 8 (42.1%) | 41 (33.3%) | |
Between the second and seventh days, n (%) | 9 (8.6%) | 1 (5.3%) | 10 (8.1%) | |
Fever | 0.019 *^ | |||
On the first day, n (%) | 17 (16.2%) | 8 (42.1%) | 25 (20.3%) | |
Between the second and seventh days, n (%) | 2 (1.9%) | 1 (5.3%) | 3 (2.4%) | |
Myalgia | 0.427 ^ | |||
On the first day, n (%) | 29 (27.6%) | 8 (41.1%) | 37 (30.1%) | |
Between the second and seventh days, n (%) | 11 (10.5%) | 2 (10.5%) | 13 (10.6%) | |
Fatigue up to the seventh day, n (%) | 54 (51.4%) | 8 (41.1%) | 0.521 ^ | 62 (50.4%) |
Gastrointestinal symptoms up to the seventh day | 0.009 *^ | |||
Total, n (%) | 9 (8.6%) | 6 (31.6%) | 15 (12.2%) | |
Nausea, n (%) | 4 (3.8%) | 3 (15.8%) | 7 (5.7%) | |
Vomiting, n (%) | 3 (2.9%) | None | 3 (2.4%) | |
Diarrhoea, n (%) | 2 (1.9%) | 3 (15.8%) | 5 (4.1%) |
Pregnant Women COVID-19 + | Non-Pregnant Women COVID-19 + | p | Total COVID-19 + | |
---|---|---|---|---|
Age, mean (SD) | 31.25 (+/−1.9)) y | 34 (+/−4.4) y | 0.242 # | N/A |
BMI, mean (SD) | 21.7 (+/−3.75) kg/m2 | 22.9 (+/−3.73) kg/m2 | 0.098 # | N/A |
One dose of the vaccine administered, n (%) | 24 (100%) | 16 (100%) | N/A | 40 (100%) |
Two doses of the vaccine administered, n (%) | 16 (66.7%) | 15 (93.6%) | N/A | 31 (77.5%) |
Side effects after first dose | ||||
Vaccination site pain total, n (%) | 24 (100%) | 16 (100%) | 1 ^ | 40 (100%) |
Cutaneous reaction total, n (%) | None | 4 (25.0%) | 0.009 *^ | 4 (10.0%) |
Headache total, n (%) | 1 (4.2%) | 4 (25.0%) | 0.134 ^ | 5 (12.5%) |
On the first day, n (%) | 1 (4.2%) | 3 (18.8%) | ||
Between the second and seventh days, n (%) | None | 1 (6.3%) | ||
Fever | 0.013 ^ | |||
On the first day, n (%) | None | 2 (12.5%) | 2 (5%) | |
Between the second and seventh days, n (%) | None | 3 (18.8%) | 3 (7.5%) | |
Myalgia | 0.028 *^ | |||
On the first day, n (%) | 1 (4.2%) | 5 (31.3%) | 6 (15.0%) | |
Between the second and seventh days, n (%) | 1 (4.2%) | 2 (12.5%) | 3 (7.5%) | |
Fatigue up to the seventh day, n (%) | 10 (41.7%) | 6 (37.5%) | 0.727 ^ | 16 (40.0%) |
Gastrointestinal symptoms up to the seventh day | 0.206 ^ | |||
Total, n (%) | None | 2 (12.5%) | 2 (5%) | |
Nausea, n (%) | None | 1 (6.3%) | 1 (2.5%) | |
Vomiting, n (%) | None | 1 (6.3%) | 1 (2.5%) | |
Diarrhoea, n (%) | None | None | None | |
Side effects after second dose | ||||
Vaccination site pain, n (%) | 14 (87.5%) | 13 (86.7%) | 0.944 ^ | 27 (87.0%) |
Cutaneous reaction total, n (%) | None | 2 (13.3%) | 0.319 ^ | 2 (6.5%) |
Headache total, n (%) | 2 (12.5%) | 4 (26.7%) | 0.160 ^ | 6 (19.4%) |
On the first day, n (%) | 2 (12.5%) | 1 (6.7%) | ||
Between the second and seventh days, n (%) | None | 3 (20.0%) | ||
Fever | 0.170 ^ | |||
On the first day, n (%) | None | 1 (6.7%) | 1 (3.2%) | |
Between the second and seventh days, n (%) | None | 2 (13.3%) | 2 (6.5%) | |
Myalgia | 0.011 *^ | |||
On the first day, n (%) | 1 (6.3%) | 3 (20.0%) | 4 (12,9) | |
Between the second and seventh days, n (%) | None | 5 (33.0%) | 5 (16,13) | |
Fatigue up to the seventh day, n (%) | 7 (43.8%) | 8 (53.3%) | 0.734 ^ | 15 (48) |
Gastrointestinal symptoms up to the seventh day | 0.684 ^ | |||
Total, n (%) | None | 2 (13.3%) | 2 (6.5%) | |
Nausea, n (%) | None | 1 (6.7%) | 1 (3.2%) | |
Vomiting, n (%) | None | None | None | |
Diarrhoea, n (%) | None | 1 (6.7%) | 1 (3.2%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zdanowski, W.; Markiewicz, A.; Zdanowska, N.; Lipińska, J.; Waśniewski, T. Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals. Vaccines 2022, 10, 200. https://doi.org/10.3390/vaccines10020200
Zdanowski W, Markiewicz A, Zdanowska N, Lipińska J, Waśniewski T. Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals. Vaccines. 2022; 10(2):200. https://doi.org/10.3390/vaccines10020200
Chicago/Turabian StyleZdanowski, Wojciech, Agnieszka Markiewicz, Natalia Zdanowska, Janina Lipińska, and Tomasz Waśniewski. 2022. "Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals" Vaccines 10, no. 2: 200. https://doi.org/10.3390/vaccines10020200
APA StyleZdanowski, W., Markiewicz, A., Zdanowska, N., Lipińska, J., & Waśniewski, T. (2022). Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals. Vaccines, 10(2), 200. https://doi.org/10.3390/vaccines10020200